Microtubules in blue, tau represented in green, and a-beta in yellow.
Image Credit: Ryan Julian/UCR
Scientific Frontline: Extended "At a Glance" Summary: Intracellular Competition of Alzheimer's Proteins
The Core Concept: Alzheimer's disease pathology may stem from amyloid-beta proteins actively competing with and displacing tau proteins inside neurons, leading to the breakdown of vital cellular transport systems.
Key Distinction/Mechanism: Moving away from the traditional view that extracellular amyloid-beta plaques are the primary cause of Alzheimer's, this model demonstrates that amyloid-beta and tau compete for the exact same binding sites on cellular microtubules. When amyloid-beta accumulates inside the neuron, it displaces tau, causing the microtubule transport system to destabilize and forcing the displaced tau to misbehave, aggregate, and migrate inappropriately.
Major Frameworks/Components:
- Microtubules: Microscopic tubular structures that function as transport "highways" for essential molecules within nerve cells. Without them, neurons cannot move materials required for survival and communication.
- Tau Protein: A protein whose primary healthy function is to bind to and stabilize microtubules.
- Amyloid-beta (a-beta): A protein previously known primarily for forming extracellular plaques, now shown to structurally resemble tau's microtubule-binding region. It binds to microtubules with similar strength to tau.
- Autophagy Decline: The theory integrates the known age-related slowing of the brain's cellular recycling system (autophagy), which normally clears proteins like a-beta before they can accumulate and compete with tau.
Branch of Science: Neuroscience, Molecular Biology, Biochemistry.
Future Application: Future therapeutic development may pivot away from simply targeting protein clumps. Instead, researchers may focus on protecting microtubule stability (potentially using stabilizing agents like lithium), preventing amyloid-beta from physically interfering with microtubules, or enhancing the cell's natural autophagy mechanisms to clear intracellular amyloid-beta.
Why It Matters: This framework reconciles multiple inconsistencies in Alzheimer's research into a single, cohesive explanation. By identifying the aggregation of amyloid-beta and tau as downstream effects of transport system failure rather than the isolated primary cause, this discovery provides a clear, highly specific cellular target for the next generation of Alzheimer's treatments.
New UC Riverside-led research suggests Alzheimer’s arises not simply from plaques forming in the brain, as is widely believed, but from one protein interfering with the normal job of another
Microtubules in blue, tau represented in green, and a-beta in yellow. (Ryan Julian/UCR)
For decades, much Alzheimer’s research has focused on the idea that clumps of amyloid beta or a-beta proteins cause the disease. Genetic mutations that increase a-beta are known to trigger early onset Alzheimer’s, reinforcing this view.
Yet thousands of clinical trials aimed at removing a-beta have failed to stop or reverse the disease.
Scientists also know that tau protein accumulates in the brains of Alzheimer’s patients. But the exact relationship between tau and a-beta has remained unclear.
“In addition to having dementia, Alzheimer’s diagnosis requires both a-beta and tau buildup in the brain,” said UCR chemistry professor and study lead author Ryan Julian. “But many labs focus on the role of one and ignore the other."
Tau’s main function is to stabilize structures inside cells called microtubules. As their name suggests, microtubules are tiny tubes. They function like highways for essential molecules to be transported to different parts of a nerve cell. Without microtubules, neurons cannot properly move materials required for survival and communication.
The researchers noticed that the regions of tau protein that attach to microtubules bear a striking resemblance to the size and structure of a-beta. That similarity raised the possibility that a-beta might also bind to microtubules.
In this study, the researchers tagged a-beta with a fluorescent marker. When its movements slowed down and the light it emitted changed, scientists could see that a-beta had attached to microtubules.
These experiments showed that a-beta and tau bind with roughly the same strength, meaning amyloid beta can displace tau if it accumulates inside neurons.
“Our work shows amyloid beta and tau compete for the same binding sites on microtubules, and that a-beta can prevent tau from functioning correctly,” Julian said.
These results suggest the disease could begin when a-beta displaces tau, causing the transport system inside nerve cells to start breaking down. Also, when not interacting with microtubules, tau begins to misbehave in other ways and starts to aggregate and migrate into parts of neurons where it doesn’t belong.
By revealing that aggregation of a-beta and tau are downstream effects rather than the primary cause, many inconsistencies in theories about Alzheimer's disease can be reconciled. For example, a-beta plaques that form outside cells might not interfere with the tau inside cells, or the microtubules that tau stabilizes.
The theory also fits with evidence that the brain’s recycling system slows with age. Autophagy normally clears proteins such as a-beta from cells. If that process slows in older adults, a-beta may accumulate and begin competing with tau for microtubule binding.
Other observations also align with the model. Recent studies have shown lithium can lower Alzheimer’s risk, while previous studies found that lithium stabilizes microtubules. This raises the possibility that protecting microtubules could counteract the disruptive effects of a-beta.
If confirmed, the findings could shift the focus of Alzheimer’s therapy. Instead of targeting protein clumps alone, researchers might aim to prevent a-beta from interfering with microtubules or enhance the cell’s ability to remove it from neurons.
Julian said the work helps connect decades of separate Alzheimer’s findings into a single explanation.
“This idea helps make sense of many results that previously seemed unrelated,” Julian said. “It gives us a clearer picture of what may be going wrong inside neurons and where new treatments might start.”
Published in journal: Proceedings of the National Academy of Sciences "Nexus"
Authors: Thomas A Shoff, Maxence Derbez-Morin, Peishan Cai, and Ryan R Julian
Source/Credit: University of California, Riverside | Jules Bernstein
Reference Number: ns031826_02
.jpg)
.jpg)